Progress and Prospects in Parkinson's Research/Symptoms/Azilect

( To subpage for editing >> ) 

AZILECT ® is prescribed as a supplement to levodopa for the treatment of Parkinson’s disease symptoms.

Active ingredients
Rasagiline

Rasagiline is an irreversible inhibitor of monoamine oxidase used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. It is selective for MAO type B over type A by a factor of fourteen.

Inactive ingredients
Mannitol

Colloidal anhydrous silica

Maize starch

Stearic acid

Talc

Most common adverse reactions to AZILECT
Very common (Affecting more tham 1 user im 10)

Dyskinesia

Headache

Common (Affecting 1 to 10 users in 100}

abdominal pain

falls

allergy

fever

flu (influenza)

general feeling of being unwell (malaise)

neeck pain

chest pain (angina pectoris)

orthostatic hypotension

decreased appetite

constipation

dry mouth

nausea and vomiting

flatulence

leucopenia(abnormal blood tests)

arthralgia (joint pain)

musculoskeletal pain

joint inflammation (arthritis)

carpal tunnel syndrome (weakness or numbness of the hands)

decreased weight

abnormal dreams

postural instability

depression

dizziness

dystonia (muscle contractions)

rhinitis (runny nose)

dermatitis (skin irritation)

conjunctivitis (eye irritation)

urinary urgency

Less common adverse reactions to AZILECT
{Affects 1 to 10 users in 1,000) 

stroke (cerebrovascular accident)

heart attack (myocardial infarction)

blistering rash (vesiculobullous rash)

Drug interactions
AZILECT should not be taken concurrently with:-

monamine oxidase (MAO) inhibitors

pethidine

St. John's Wort